secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001104659-23-071597
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex shareholders elect directors, approve 600K share increase, say-on-pay at 1 year
--------------------------------------------------------------------------------

- All 9 director nominees elected; Dr. Garry A. Neil received highest opposition with 6.2M against.
- Ratification of PwC as auditor for FY2023 approved with 43.4M for, 98.6K against.
- Amendment to 2021 Omnibus Equity Incentive Plan approved, increasing share reserve by 600K to 4.3M shares.
- Advisory say-on-pay passed with 38.7M for; frequency set at 1 year (39.0M voted for 1 year).
- Board determined future say-on-pay votes will occur annually until next frequency vote (by 2029).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465923071597/0001104659-23-071597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465923071597/tm2318812d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-071597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer